Business Wire

NAGA Turns Profitable - Record Sales of EUR 7 Million With a Net Profit of EUR + 2.1 Million for the First Quarter

Share

The NAGA Group closed the first quarter of 2020 with a provisional record result of EUR 7 million in sales (Q1/2019: EUR 0.6 million) and a provisional net profit of EUR + 2.1 million (Q1/2019: EUR - 3.9 million loss). The unaudited EBITDA stands at EUR + 3.3 million (Q1/2019: EUR - 2.8 million), whilst unaudited EBIT is at EUR + 2.2 million (Q1/2019: EUR - 3.9 million). With an all-time high of 1.2 million trades for the quarter, also a record trading volume of EUR 23 billion was recorded. In addition, customers deposited more than EUR 12.5 million into the platform, which was the highest in a quarter. The number of active accounts has doubled since the beginning of the year, while the number of new registrations has tripled.

"Thus the turnaround is apparent for NAGA. Looking back to our very beginnings it is extremely positive that we turned this FinTech profitable in less than 5 years since inception. Especially after the challenges we faced last year, when we had to take extreme measures, showed us that a startup story can have both ups and downs. But strict discipline, forward-thinking and consistently pursuing our vision have brought us to where we are today. Personally, I am pleased with the cash flow-relevant EBITDA which gives us further strength in order to implement our high growth ambitions. We are already running a self-sustaining business, that was our primary goal for 2020. Our cost structure and operating structure today is very lean and dynamic. The entire NAGA organization can therefore adapt to growth just as quickly as last year to the restructuring", explained Benjamin Bilski, founder and CEO of NAGA.

Especially during the Corona virus crisis NAGA has adapted very quickly. The company has set up a full remote-working environment whilst ensuring that the platform works without any interruptions. On the technological side NAGA increase the system capacity and was able to scale with rising client's requests and transaction volumes. "We have seen from the trading industry that numerous firms - especially in Germany - halted trading temporarily and had severe issues. NAGA had full uptime of our execution engine. It proves that our focus on proprietary technology and infrastructure pays off".

NAGA will continue to grow its business on a global scale. The company expects further growth results from the recently started initiatives in Uruguay as well as in China.

"After the strong Q4 2019 we have confirmed that the growth was indeed sustainable. We will be now more attentive than ever when it comes to our business development and strategic decision of investing money. We still have significant room for improvements and growth. The overall market interest for online-trading and especially in user-friendly concepts like NAGA's is growing fast. We will continue to identify new markets and roll out both our marketing and sales initiatives. I am confident that our shareholders and the market appreciate our growth path. The trust in our concept is building and in my opinion it should also be reflected in our share price", concludes Benjamin Bilski.

###

About NAGA

NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical Mastercard and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.

Language:English
Company:The NAGA Group AG
Hohe Bleichen 12
20354 Hamburg
Germany
E-mail:info@naga.com
Internet:www.naga.com
ISIN:DE000A161NR7
WKN:A161NR
Indices:Scale 30
Listed:Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange

Contact information

Name: Benjamin Bilski
Tel: +49 (0)40 5247 79153
Email: ben@naga.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CESTPress release

The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na

TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CESTPress release

TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CESTPress release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio

JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine

U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom